Table 1.

Demographic Data of the Participants and Their Medications.

				All patients
Demographics		Number of patients		451
		Ulcerative colitis/Crohn’s disease		241/210
		Sex: male/female		287/164
		Age at enrollment (years), median (IQR)		46 (35-55)
		Age at diagnosis (years), median (IQR)		28 (20-39)
		Disease duration (years), median (IQR)		13.0 (6.0-23.5)
Medication		Mesalamine, n (%)		337 (74.7%)
		Corticosteroids, n (%)		16 (3.5%)
		Immunomodulators, n (%)		134 (29.7%)
		Anti-tumor necrosis factor therapy, n (%)		140 (31.0%)
		Ustekinumab, n (%)		26 (5.8%)
		Vedolizumab, n (%)		18 (4.0%)
		Tofacitinib, n (%)		6 (1.3%)

IQR: interquartile range